TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26
|
作者：
Ahn, M. [1 ]
Han, J. [2 ]
Sequist, L. [3 ]
Cho, B. C. [4 ]
Lee, J. S. [5 ]
Kim, S. [6 ]
Su, W. [7 ]
Tsai, C. [8 ]
Yang, J. C. [9 ]
Yu, H. [10 ]
Horn, L. [11 ]
Lee, K. [12 ]
Haddad, V. [13 ]
Frigault, M. [14 ]
Ahmed, G. [13 ]
Yang, L. [15 ]
Ghiorghiu, D. [13 ]
Oxnard, G. [16 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Taipei, Taiwan
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan
[13] Astrazeneca, Cambridge, England
[14] Astrazeneca, Waltham, MA USA
[15] Astrazeneca, Shanghai, Peoples R China
[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; EGFR-Mutant; MET-amplification;
D O I：
10.1016/j.jtho.2017.09.377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 09.03
引用
收藏
页码：S1768 / S1768
页数：1
相关论文
共 50 条
  • [31] Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
    White, Maya N.
    Piper-Vallillo, Andrew J.
    Gardner, Rebecca M.
    Cunanan, Kristen
    Neal, Joel W.
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Chen, Thomas T.
    Sequist, Lecia, V
    Piotrowska, Zofia
    Wakelee, Heather A.
    CLINICAL LUNG CANCER, 2022, 23 (03) : E210 - E221
  • [32] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
    Lu, S.
    Cheng, Y.
    Wu, L.
    Fang, J.
    Li, B.
    Han, L.
    Zhang, Y.
    Pan, H.
    Wang, Z.
    Sun, Y.
    Ye, F.
    Hu, Y.
    Yu, W.
    Zhou, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
  • [33] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [34] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [35] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
    Gan, Jiadi
    Huang, Yihua
    Liao, Jun
    Pang, Lanlan
    Fang, Wenfeng
    ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
  • [36] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [37] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
    Elghawy, Omar
    Barsouk, Adam
    Reed-Guy, Lauren
    Stalker, Margaret
    Sussman, Jonathan
    Robinson, Kyle
    Kosteva, John
    Singh, Aditi
    Cohen, Roger B.
    Langer, Corey
    Ciunci, Christine
    D'Avella, Christopher
    Sun, Lova
    Marmarelis, Melina E.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2025, 26 (02)
  • [38] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
    Jin-Ji Yang
    Jian Fang
    Yong-Qian Shu
    Jian-Hua Chang
    Gong-Yan Chen
    Jian Xing He
    Wei Li
    Xiao-Qing Liu
    Nong Yang
    Caicun Zhou
    Jian An Huang
    Melanie M. Frigault
    Ryan Hartmaier
    Ghada F. Ahmed
    Coumaran Egile
    Shethah Morgan
    Remy B. Verheijen
    Anders Mellemgaard
    Liu Yang
    Yi-Long Wu
    Investigational New Drugs, 2021, 39 : 477 - 487
  • [39] The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
    Ebisudani, Toshiki
    Nakashima, Kei
    Misawa, Masafumi
    Tokumoto, Akiko
    Nemoto, Masahiro
    Tsuzuki, Ryuta
    Suzuki, Fumi
    Yamawaki, Satoshi
    Otsuki, Ayumu
    Noma, Satoshi
    Aoshima, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1208 - S1209
  • [40] Tepotinib plus gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study
    Yang, James Chih-Hsin
    Zhou, Jianying
    Kim, Dong-Wan
    Ahmad, Azura Rozila
    Soo, Ross Andrew
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Park, Keunchil
    Wu, Yi-Long
    CANCER RESEARCH, 2019, 79 (13)
12345